VOLUME 2 (2011)
View Archive »
About The Cover
Histological and immunohistochemical analyses of pancreatic sections from
p16flox/flox; Pdx1-Cre mice showed normal development of pancreatic cell lineages with significant reduction of p16 protein expression. See
Qui et al.
Table of Contents
|
| Novel Insights into FHassociated Disease are KEAPing the Lid on Oncogenic HIF Signalling |
|
https://doi.org/10.18632/oncotarget.348
|
| 820-821 |
|
| Circulating tumor cells in the cerebrospinal fluid: “tapping†into diagnostic and predictive potential |
|
https://doi.org/10.18632/oncotarget.349
|
| 822-822 |
|
| Glutamate and tumorassociated epilepsy |
|
https://doi.org/10.18632/oncotarget.350
|
| 823-824 |
|
| Lowdose Erythropoietin reduces risk of heart failure induced by anticancer therapy |
|
https://doi.org/10.18632/oncotarget.352
|
| 825-825 |
|
| Microsatellite Instability in Colorectal Cancer: Time to Stop Hiding |
|
https://doi.org/10.18632/oncotarget.353
|
| 826-827 |
|
| Targeting allosteric regulatory modules in oncoproteins: “Drugging the Undruggable†|
|
https://doi.org/10.18632/oncotarget.354
|
| 828-829 |
Special Feature: Editorial
|
| FACT in Cell Differentiation and Carcinogenesis |
|
https://doi.org/10.18632/oncotarget.356
|
| 830-832 |
Research Papers
|
| Abrogation of PIK3CA or PIK3R1 reduces proliferation migration and invasion in glioblastoma multiforme cells |
|
https://doi.org/10.18632/oncotarget.346
|
| 833-849 |
|
| Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin A single center experience |
|
https://doi.org/10.18632/oncotarget.347
|
| 850-861 |
|
| Disruption of p16 and Activation of Kras in Pancreas Increase Ductal Adenocarcinoma Formation and Metastasis in vivo |
|
https://doi.org/10.18632/oncotarget.357
|
| 862-873 |
|
| Mechanisms of AXL overexpression and function in Imatinibresistant chronic myeloid leukemia cells |
|
https://doi.org/10.18632/oncotarget.360
|
| 874-885 |
Research Perspectives
|
| ARID2: A new tumor suppressor gene in hepatocellular carcinoma |
|
https://doi.org/10.18632/oncotarget.355
|
| 886-891 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß